clinical trial · NCT03953300
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
AsthmaBenralizumabPlacebo
brief summary
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
started
Oct 8, 2019
primary completion
Oct 19, 2026
completion
Oct 19, 2026
last updated
May 5, 2026
official title
A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol